<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970875</url>
  </required_header>
  <id_info>
    <org_study_id>NHR010619</org_study_id>
    <nct_id>NCT04970875</nct_id>
  </id_info>
  <brief_title>Partial Modified Blair Incision on Benign Tumor Parotidectomy Scar's Characteristics</brief_title>
  <acronym>MiniBlair</acronym>
  <official_title>Effect of Parotid Mass Location on Benign Tumor Parotidectomy Scar's Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Galilee Hospital-Nahariya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Galilee Hospital-Nahariya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parotidectomy is the treatment of choice for tumors in the parotid gland, with the modified&#xD;
      Blair is the most common incision used. In our medical center, the incision is tailored to&#xD;
      the size and location of the specific parotid tumor. This retrospective analysis aims to&#xD;
      determine the incidence of complications and to assess the relation between the mass and scar&#xD;
      characteristics in patients who had undergone parotidectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scar characteristics of patient who had undergone parotidectomy for benign neoplasms at&#xD;
      our medical center between 2013 and 2019 will be evaluated. Patients will complete a&#xD;
      questionnaire regarding the occurrence of complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by a questionnaire.</measure>
    <time_frame>1 Year</time_frame>
    <description>The Warmald Parotidectomy Complications Questionnaire consists of five items, each addressing a complication common to parotidectomy: numbness of the ear on the operated side, Frey's syndrome, facial depression or deformity, noticeable scar, and pain or discomfort in the scar. Subjects are asked to indicate the extent to which they were disturbed by each of these complications on a scale ranging from 1 (never) to 10 (always).</description>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Salivary Gland Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>QoL questionnaire</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The scar characteristics of patient who had undergone parotidectomy for benign neoplasms at&#xD;
        our medical center between 2013 and 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18 years during the surgery&#xD;
&#xD;
          -  Clinical diagnosis of a benign parotid pathology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A malignant pathology of the parotid gland&#xD;
&#xD;
          -  Unavailable data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

